WO2017100726A1 - Methods for treatng huntington's disease - Google Patents

Methods for treatng huntington's disease Download PDF

Info

Publication number
WO2017100726A1
WO2017100726A1 PCT/US2016/066042 US2016066042W WO2017100726A1 WO 2017100726 A1 WO2017100726 A1 WO 2017100726A1 US 2016066042 W US2016066042 W US 2016066042W WO 2017100726 A1 WO2017100726 A1 WO 2017100726A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino
methyl
tetramethylpiperidin
pyridazin
pyrazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2016/066042
Other languages
English (en)
French (fr)
Other versions
WO2017100726A8 (en
Inventor
Suresh Babu
Anuradha Bhattacharyya
Seongwoo Hwang
Minakshi JANI
Young-Choon Moon
Nadiya Sydorenko
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PTC Therapeutics Inc
Original Assignee
PTC Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59013375&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2017100726(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to MX2021001091A priority Critical patent/MX391850B/es
Priority to MX2018007022A priority patent/MX382671B/es
Priority to PL16874024T priority patent/PL3386511T3/pl
Priority to IL294124A priority patent/IL294124B2/en
Priority to SI201631243T priority patent/SI3386511T1/sl
Priority to EA201800367A priority patent/EA201800367A1/ru
Priority to CN201680081666.1A priority patent/CN108697709A/zh
Priority to CN201911286032.1A priority patent/CN110946865B/zh
Priority to EP16874024.9A priority patent/EP3386511B2/en
Priority to NZ743147A priority patent/NZ743147B2/en
Priority to JP2018529967A priority patent/JP2019500352A/ja
Priority to DK16874024.9T priority patent/DK3386511T3/da
Priority to LTEP16874024.9T priority patent/LT3386511T/lt
Priority to SG11201804915RA priority patent/SG11201804915RA/en
Priority to AU2016366694A priority patent/AU2016366694C1/en
Application filed by PTC Therapeutics Inc filed Critical PTC Therapeutics Inc
Priority to KR1020187016467A priority patent/KR102488323B1/ko
Priority to ES16874024T priority patent/ES2879995T3/es
Priority to CN202110932557.9A priority patent/CN113717154B/zh
Priority to KR1020227021757A priority patent/KR20220100719A/ko
Priority to US15/781,303 priority patent/US10874672B2/en
Priority to CA3007412A priority patent/CA3007412C/en
Priority to IL281633A priority patent/IL281633B/en
Priority to EP21158464.4A priority patent/EP3848035B1/en
Publication of WO2017100726A1 publication Critical patent/WO2017100726A1/en
Priority to IL259843A priority patent/IL259843B/en
Priority to PH12018501226A priority patent/PH12018501226A1/en
Anticipated expiration legal-status Critical
Publication of WO2017100726A8 publication Critical patent/WO2017100726A8/en
Priority to US16/710,515 priority patent/US10881658B2/en
Priority to AU2020201380A priority patent/AU2020201380B2/en
Priority to US17/093,194 priority patent/US11638706B2/en
Priority to US18/111,421 priority patent/US20230201200A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Definitions

  • the present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.
  • the present description relates to substituted monocyclic heteroaryl compounds, forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.
  • Huntington's disease is a progressive, autosomal dominant neurodegenerative disorder of the brain, having symptoms characterized by involuntary movements, cognitive impairment, and mental deterioration. Death, typically caused by pneumonia or coronary artery disease, usually occurs 13 to 15 years after the onset of symptoms. The prevalence of HD is between three and seven individuals per 100,000 in populations of western European descent. In North America, an estimated 30,000 people have HD, while an additional 200,000 people are at risk of inheriting the disease from an affected parent.
  • the disease is caused by an expansion of uninterrupted trinucleotide CAG repeats in the "mutant" huntingtin (Htt) gene, leading to production of HTT (Htt protein) with an expanded poly-glutamine (polyQ) stretch, also known as a "CAG repeat” sequence.
  • Htt huntingtin
  • polyQ poly-glutamine
  • the present description relates to methods for treating or ameliorating HD in a subject in need thereof comprising administering to the subject an effective amount of a compound of Formula (I): N— N
  • W, X, A and B are as defined herein, or forms and compositions thereof.
  • the present description relates to a use of a compound of Formula (I) or a form or composition thereof in a method for treating or ameliorating HD in a subject in need thereof comprising, administering an effective amount of the compound or a form or
  • composition thereof, to the subject is
  • the present description further relates to the use of a compound of Formula (I) or a form thereof in combination with agents having additive or synergistic activity, thus providing a combination product for the treatment of HD.
  • the present description relates to a method or use of a compound for treating or ameliorating HD in a subject in need thereof comprising administering to the subject an effective amount of a compound of Formula (I :
  • A is aryl, heteroaryl, heterocyclyl, or C9_iocycloalkyl
  • aryl is selected from phenyl and naphthyl, each optionally substituted with 1, 2, 3, or 4 substituents each selected from Ri,
  • heteroaryl is a saturated monocyclic, bicyclic or tricyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from Ri
  • heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or tricyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R 2
  • C9_iocycloalkyl is a saturated or partially unsaturated bicyclic ring system optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R 2 ;
  • heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or polycyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R 4 ;
  • Ri is halogen, hydroxyl, cyano, Ci_ 4 alkyl, halo-Ci_ 4 alkyl, amino, Ci_ 4 alkyl- amino,
  • heteroaryl-C i_ 4 alkyl-amino heteroaryl-C i_ 4 alkyl-amino, heteroaryl-C i_ 4 alkyl-amino-carbonyl,
  • heteroaryl-C i_ 4 alkyl-carbonyl-amino heteroaryl-C i_ 4 alkyl-amino-carbonyl-C i_ 4 alkyl, heteroaryl-C i_ 4 alkyl-carbonyl-amino-C i_ 4 alkyl, heterocyclyl, heterocyclyl-C i- 4 alkyl, heterocyclyl-Ci- 4 alkoxy, phenyl, or phenyl-Ci_ 4 alkoxy,
  • heteroaryl is a saturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S,
  • heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S, and
  • R 2 is halogen, hydroxyl, cyano, oxo, hydroxyl-imino, Ci- 4 alkyl, halo-Ci- 4 alkyl, amino, Ci- 4 alkyl-amino, (Ci_ 4 alkyl) 2 -amino, amino-Ci- 4 alkyl, Ci- 4 alkyl-amino-Ci- 4 alkyl,
  • heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S, and
  • heterocyclyl is optionally substituted with 1, or 2 substituents each selected from R 3 ;
  • R 3 is halogen, hydroxyl, nitro, oxo, hydroxyl-imino, Ci- 4 alkyl, halo-Ci- 4 alkyl, amino,
  • Ci_ 4 alkyl 2 -amino-carbonyl, Ci_ 4 alkyl-amino-carbonyl-Ci_ 4 alkyl, (Ci_ 4 alkyl) 2 -amino- carbonyl-Ci- 4 alkyl, Ci- 4 alkyl-carbonyl-amino, Ci- 4 alkyl-carbonyl-amino-Ci- 4 alkyl, hydroxyl-Ci_ 4 alkyl, Ci- 4 alkyl-carbonyl, Ci- 4 alkoxy, halo-Ci- 4 alkoxy, amino-Ci- 4 alkoxy, hydroxyl-C i_ 4 alkoxy, C i_ 4 alkyl-C i- 4 alkoxy, C i_ 4 alkyl-amino-C i_ 4 alkoxy,
  • heteroaryl-C i_ 4 alkyl-amino heteroaryl-C i_ 4 alkyl-amino, heteroaryl-C i_ 4 alkyl-amino-carbonyl,
  • heteroaryl-C i_ 4 alkyl-carbonyl-amino heteroaryl-C i_ 4 alkyl-amino-carbonyl-C i- 4 alkyl, heteroaryl-C i_ 4 alkyl-carbonyl-amino-C i- 4 alkyl, heterocyclyl, heterocyclyl-C i- 4 alkyl, phenyl, or phenyl-Ci- 4 alkoxy;
  • R4 is independently selected from halogen, Ci_ 4 alkyl, hydroxyl-C i_ 4 alkyl, amino, Ci ⁇ alkyl- amino, (Ci_ 4 alkyl) 2 -amino or hydroxyl-C i_ 4 alkyl-amino; and
  • R5 is hydrogen, Ci- 4 alkyl, or hydroxyl-C i- 4 alkyl
  • a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.
  • An embodiment of the present description further relates to a method or use of a compound for treating or ameliorating HD in a subject in need thereof comprising administering to the subject an effective amount of a compound of Formula (I) selected from a compound of Formula (la) and Formula (lb :
  • A is aryl, heteroaryl, heterocyclyl, or C9_iocycloalkyl
  • aryl is selected from phenyl and naphthyl, each optionally substituted with 1, 2, 3, or 4 substituents each selected from Ri,
  • heteroaryl is a saturated monocyclic, bicyclic or tricyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from Ri,
  • heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or tricyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R 2
  • C9_iocycloalkyl is a saturated or partially unsaturated bicyclic ring system optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R 2 ;
  • heterocyclyl is a saturated or partially unsaturated monocyclic, bicyclic or polycyclic ring system having 1, 2, or 3 heteroatom ring members independently selected from N, O, or S, each optionally substituted with 1, 2, 3, 4, or 5 substituents each selected from R 4 ;
  • Ri is halogen, hydroxyl, cyano, Ci_ 4 alkyl, halo-Ci_ 4 alkyl, amino, Ci_ 4 alkyl- amino,
  • heteroaryl-C i_ 4 alkyl-amino heteroaryl-C i_ 4 alkyl-amino, heteroaryl-C i_ 4 alkyl-amino-carbonyl,
  • heteroaryl-C i_ 4 alkyl-carbonyl-amino heteroaryl-C i_ 4 alkyl-amino-carbonyl-C i- 4 alkyl, heteroaryl-C i_ 4 alkyl-carbonyl-amino-C i- 4 alkyl, heterocyclyl, heterocyclyl-C i- 4 alkyl, heterocyclyl-Ci- 4 alkoxy, phenyl, or phenyl-Ci_ 4 alkoxy,
  • heteroaryl is a saturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S,
  • heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S, and
  • R 2 is halogen, hydroxyl, cyano, oxo, hydroxyl-imino, Ci- 4 alkyl, halo-Ci- 4 alkyl, amino,
  • R 3 is halogen, hydroxyl, nitro, oxo, hydroxyl-imino, Ci- 4 alkyl, amino, Ci- 4 alkyl-amino,
  • heteroaryl-C i_ 4 alkyl-amino heteroaryl-C i_ 4 alkyl-amino, heteroaryl-C i_ 4 alkyl-amino-carbonyl,
  • R 4 is independently selected from halogen, Ci_ 4 alkyl, hydroxyl-Ci_ 4 alkyl, amino, Ci ⁇ alkyl- amino, (Ci_ 4 alkyl)2-amino or hydroxyl-Ci_ 4 alkyl-amino;
  • R5 is hydrogen, Ci_ 4 alkyl, or hydroxyl-Ci_ 4 alkyl
  • a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.
  • Another embodiment of the present description further relates to methods for treating or ameliorating HD in a subject in need thereof comprising administering to the subject an effective amount of a compound of Formula (I) selected from a compound of Formula (la) and Formula (lb):
  • X is O, NH, N(CH 3 ) or a bond
  • A is aryl, heteroaryl or heterocyclyl
  • aryl is selected from the group consisting of:
  • heteroar l is selected from the group consisting of
  • Ri a , Ri b and Ri c are each, where allowed by available valences, one or more substituents each selected from halogen, hydroxyl, cyano, Ci- 4 alkyl, halo-Ci- 4 alkyl, amino,
  • Ci_ 4 alkyl 2 -amino-carbonyl, Ci_ 4 alkyl-amino-carbonyl-Ci_ 4 alkyl, (Ci_ 4 alkyl) 2 -amino- carbonyl-Ci- 4 alkyl, Ci- 4 alkyl-carbonyl-amino, Ci- 4 alkyl-carbonyl-amino-Ci- 4 alkyl, hydroxyl-Ci_ 4 alkyl, Ci- 4 alkyl-carbonyl, Ci- 4 alkoxy, halo-Ci- 4 alkoxy, amino-Ci- 4 alkoxy, hydroxyl-C i_ 4 alkoxy, C i_ 4 alkyl-C i_ 4 alkoxy, C i_ 4 alkyl-amino-C i_ 4 alkoxy,
  • heteroaryl-C i_ 4 alkyl-carbonyl-amino heteroaryl-C i_ 4 alkyl-amino-carbonyl-C i- 4 alkyl, heteroaryl-C i_ 4 alkyl-carbonyl-amino-C i- 4 alkyl, heterocyclyl, heterocyclyl-C i- 4 alkyl, heterocyclyl-Ci- 4 alkoxy, phenyl, or phenyl-Ci_ 4 alkoxy,
  • heteroaryl is a saturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S,
  • heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S, and
  • R 2a , R 2b and R 2C are each, where allowed by available valences, one or more substituents each selected from halogen, hydroxyl, cyano, oxo, hydroxyl-imino, Ci_ 4 alkyl, halo-Ci_ 4 alkyl, amino, Ci_ 4 alkyl-amino, (Ci_ 4 alkyl) 2 -amino, amino-Ci_ 4 alkyl, Ci_ 4 alkyl-amino-Ci_ 4 alkyl, (Ci- 4 alkyl) 2 -amino-Ci_ 4 alkyl, amino-carbonyl, hydroxyl-Ci- 4 alkyl, Ci- 4 alkoxy,
  • Ci- 4 alkoxy-carbonyl C 2 - 4 alkenyl, C3_ 7 cycloalkyl, or heterocyclyl-Ci- 4 alkyl
  • heterocyclyl is a saturated or partially unsaturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S, and
  • heterocyclyl is optionally substituted with 1, or 2 substituents each selected from R 3 ;
  • R 3 is halogen, hydroxyl, nitro, oxo, hydroxyl-imino, Ci_ 4 alkyl, amino, Ci_ 4 alkyl-amino,
  • heteroaryl-C i_ 4 alkyl-amino heteroaryl-C i_ 4 alkyl-amino, heteroaryl-C i_ 4 alkyl-amino-carbonyl,
  • heteroaryl-C i_ 4 alkyl-carbonyl-amino heteroaryl-C i_ 4 alkyl-amino-carbonyl-C i_ 4 alkyl, heteroaryl-C i_ 4 alkyl-carbonyl-amino-C i_ 4 alkyl, heterocyclyl, heterocyclyl-C i_ 4 alkyl, phenyl, or phenyl-Ci- 4 alkoxy;
  • R4a, R4b, R4c, R4d, R4e, 3 ⁇ 44f and R4 g are independently selected from halogen, Ci-4alkyl,
  • a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.
  • a compound of Formula (I) selected from a com ound of Formula (lal 1), Formula (Ial5), Formula (Ial8) or Formula (Ibl):
  • X is selected from O, NR 5 , or a bond
  • A is selected from phenyl, thiophenyl, indazolyl, pyridinyl, pyrimidinyl or phenoxy, wherein phenyl and phenoxy are each optionally substituted with 1, 2 or 3 substituents each selected from Ri a ,
  • thiophenyl, indazolyl, pyridinyl, pyrimidinyl are each optionally substituted with 1 or 2 substituents each selected from Ri a ,
  • B is selected from lH-pyrazolyl, piperidinyl, 1,2,3,6-tetrahydropyridinyl, ( IR,5S)-S- azabicyclo[3.2.1]octyl, 8-azabicyclo[3.2.1]oct-2-enyl, 2,6-diazaspiro[3.4]octyl or 2,7- diazaspiro[3.5]nonyl, each optionally substituted with 1 or 2 substituents each selected from R 4a ;
  • Ri a is selected from halogen, hydroxyl, Ci_ 4 alkyl, halo-Ci_ 4 alkyl, amino, Ci_ 4 alkoxy, or
  • heteroaryl is a saturated monocyclic or bicyclic ring system having 1, 2, or 3 heteroatom ring members selected from N, O, and S optionally substituted with 1 or 2 substituents each selected from R 3a ;
  • R 3a is selected from nitro or Ci_ 4 alkyl
  • R 4a is Ci- 4 alkyl
  • R5 a is hydrogen, Ci_ 4 alkyl, or hydroxyl-Ci_ 4 alkyl; wherein a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.
  • Another aspect of the present description relates to a compound of Formula (I) selected from a compound of Formula (lal 1), Formula (Ial5), Formula (Ial8) or Formula (Ibl):
  • Ri a is selected from fluoro, chloro, hydroxyl, methyl, difluoromethyl, amino, methoxy or 1H- pyrazolyl or lH-imidazol-l-yl,
  • lH-pyrazolyl is optionally substituted with 1 or 2 substituents each selected from R 3a ;
  • R 3a is selected from nitro or methyl or amino;
  • R 4a is methyl or ethyl
  • Rs a is hydrogen or methyl
  • a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.
  • Another embodiment of the method of the present description includes the use of a compound of Formula (la) or a form thereof selected from a compound of Formula (lal) or a form thereof, wherein substituents Ri a , Ri b , and X, when present, are indicated in the table below with multiple substituents separated by a comma; and, "— " indicates that one or more Ri a , R ⁇ , and X substituents are not present:
  • Another embodiment of the method of the present description includes the use of a compound of Formula (la) or a form thereof selected from a compound of Formula (Ia2) or a form thereof, wherein substituents Ri a , Ri b , and R 4a , when present, are indicated in the table below with multiple substituents separated by a comma; and, "— " indicates that one or more Ri a , Ri , and R 4a substituents are not present:
  • Another embodiment of the method of the present description includes the use of a compound of Formula (la) or a form thereof selected from a compound of Formula (Ia3) or a form thereof, wherein substituents Ri a , and X, when present, are indicated in the table below with multiple substituents separated by a comma; and, "— " indicates that one or more Ri a , and X substituents are not present:
  • Another embodiment of the method of the present description includes the use of a compound of Formula (la) or a form thereof selected from a compound of Formula (Ia4) or a form thereof, wherein substituents X, Ri a , Ri b and R 4a , when present, are indicated in the table below; and, "— " indicates that one or more X, Ri a , Ri b and R 4a substituents are not present:
  • Another embodiment of the method of the present description includes the use of a compound of Formula (la) or a form thereof selected from a compound of Formula (Ia5) or a form thereof, wherein substituents Ri a and Ri b , when present, are indicated in the table below with multiple substituents separated by a comma; and, "— " indicates that one or more Ri a and substituents are not present:
  • Another embodiment of the method of the present description includes the use of a compound of Formula (la) or a form thereof selected from a compound of Formula (Ia6) or a form thereof, wherein substituents Ri a , when present, are indicated in the table below; and, "— indicates that one or more Ri a substituents are not present:
  • Another embodiment of the method of the present description includes the use of a compound of Formula (la) or a form thereof selected from a compound of Formula (Ia7) or a form thereof, wherein substituents Ri a , when present, are indicated in the table below; and, "— indicates that one or more Ri a substituents are not present:
  • Another embodiment of the method of the present description includes the use of a compound of Formula (la) or a form thereof selected from a compound of Formula (Ia8) or a form thereof, wherein substituents Ri a and B, when present, are indicated in the table below; and, "— " indicates that one or more Ri a and B substituents are not present:
  • Another embodiment of the method of the present description includes the use of a compound of Formula (la) or a form thereof selected from a compound of Formula (Ia9) or a form thereof, wherein substituents Ri a and B, when present, are indicated in the table below; and, "— " indicates that one or more Ri a and B substituents are not present:
  • Another embodiment of the method of the present description includes the use of a compound of Formula (la) or a form thereof selected from a compound of Formula (la 10) or a form thereof, wherein substituents Ri a and B, when present, are indicated in the table below; and, "— " indicates that one or more Ri a and B substituents are not present:
  • Another embodiment of the method of the present description includes the use of a compound of Formula (la) or a form thereof selected from a compound of Formula (lal 1) or a form thereof, wherein substituents A, X and R 4a , when present, are indicated in the table below; and, "— " indicates that one or more A, X and R 4a substituents are not present:
  • Another embodiment of the present description includes a compound of Formula (la) or a form thereof selected from a compound of Formula (lal 1) or a form thereof, wherein
  • Another embodiment of the method of the present description includes the use of a compound of Formula (la) or a form thereof selected from a compound of Formula (lal 1) or a form thereof, wherein substituents A, X and R 4a , when present, are indicated in the table below; and, "— " indicates that one or more A, X and R 4a substituents are not present:
  • Another embodiment of the method of the present description includes the use of a compound of Formula (la) or a form thereof selected from a compound of Formula (la 12) or a form thereof, wherein substituents X, Ri a and B, when present, are indicated in the table below; and, "— " indicates that one or more X, Ri a and B substituents are not present:
  • Another embodiment of the method of the present description includes the use of a compound of Formula (la) or a form thereof selected from a compound of Formula (Ial3) or a form thereof, wherein substituents X, Ri a and R 4a , when present, are indicated in the table below; and, "— " indicates that one or more X, Ri a and R 4a substituents are not present:
  • Another embodiment of the method of the present description includes the use of a compound of Formula (la) or a form thereof selected from a compound of Formula (la 14) or a form thereof, wherein substituents X and B, when present, are indicated in the table below; and, "— " indicates that one or more X and B substituents are not present:
  • Another embodiment of the method of the present description includes the use of a compound of Formula (la) or a form thereof selected from a compound of Formula (Ial5) or a form thereof, wherein substituents X, Ri a and R 4a , when present, are indicated in the table below; and, "— " indicates that one or more X, Ri a and R 4a substituents are not present:
  • Another embodiment of the present description includes a compound of Formula (la) or a form thereof selected from a compound of Formula (Ial5) or a form thereof, wherein
  • Another embodiment of the method of the present description includes the use of a compound of Formula (la) or a form thereof selected from a compound of Formula (Ial5) or a form thereof, wherein substituents X, Ri a and R 4a , when present, are indicated in the table below; and, "— " indicates that one or more X, Ri a and R 4a substituents are not present:
  • Another embodiment of the method of the present description includes the use of a compound of Formula (la) or a form thereof selected from a compound of Formula (la 16) or a form thereof, wherein substituents Ri a and R4 a , when present, are indicated in the table below; and, "— " indicates that one or more Ri a and R 4a substituents are not present:
  • Another embodiment of the method of the present description includes the use of a compound of Formula (la) or a form thereof selected from a compound of Formula (Ial7) o form thereof, wherein substituent Ri a , when present, is indicated in the table below; and, "— indicates that one or more Ri a substituents are not present:
  • Another embodiment of the present description includes a compound of Formula (la) or a form thereof selected from a compound of Formula (Ial8) or a form thereof, wherein
  • Another embodiment of the method of the present description includes the use of a compound of Formula (la) or a form thereof selected from a compound of Formula (Ial8) or a form thereof, wherein substituents X, Ri a and B, when present, are indicated in the table below; and, "— " indicates that one or more X, Ri a and B substituents are not present:
  • Another embodiment of the method of the present description includes the use of a compound of Formula (lb) or a form thereof selected from a compound of Formula (Ibl) or a form thereof, wherein substituent A is indicated in the table below:
  • Another embodiment of the present description includes a compound of Formula (lb) or a form thereof selected from a compound of Formula (Ibl) or a form thereof, wherein substituent A is indicated in the table below
  • Another embodiment of the method of the present description includes the use of a compound of Formula (lb) or a form thereof selected from a compound of Formula (Ibl) or a form thereof, wherein substituent A is indicated in the table below:
  • Another embodiment of the method of the present description includes the use of a compound of Formula (lb) or a form thereof selected from a compound of Formula (Ib2) or a form thereof, wherein substituent A is indicated in the table below:
  • Another embodiment of the method of the present description includes the use of a compound of Formula (lb) or a form thereof selected from a compound of Formula (Ib3) or a form thereof, wherein substituents Ri a , and B, when present, are indicated in the table below; and, "— " indicates that one or more Ri a , and B substituents are not present:
  • Another embodiment of the ccpresent description includes the use of a compound of Formula (lb) or a form thereof selected from a compound of Formula (Ib4) or a form thereof, wherein substituents Ri a , R ⁇ , Ri c , Ri d (each representative of the scope of Ri) and X, when present, are indicated in the table below; and, "— " indicates that one or more Ri a , R ⁇ , Ri c , Ri d and X substituents are not present:
  • Another embodiment of the method of the present description includes the use of a compound of Formula (lb) or a form thereof selected from a compound of Formula (Ib5) or a form thereof, wherein substituents Ri a , R ⁇ , Ri c , Ri d (each representative of the scope of Ri) and R 4a , when present, are indicated in the table below; and, "— " indicates that one or more Ri a , R ⁇ , Ri c , Ri d and R4 a substituents are not present:
  • Another embodiment of the method of the present description includes the use of a compound of Formula (lb) or a form thereof selected from a compound of Formula (Ib6) or a form thereof, wherein substituents Ri a , R ⁇ , Ri c and R ⁇ (each representative of the scope of Ri), when present, are indicated in the table below; and, "— " indicates that one or more Ri a , Ri b , Ri c and Ri d substituents are not present:
  • Another embodiment of the method of the present description includes the use of a compound of Formula (lb) or a form thereof selected from a compound of Formula (Ib7) or a form thereof, wherein substituent Ri b , when present, is indicated in the table below:
  • Another embodiment of the method of the present description includes the use of a compound of Formula (lb) or a form thereof selected from a compound of Formula (Ib8) or a form thereof, wherein substituent Rib, when present, is indicated in the table below:
  • An embodiment of the use of a compound of Formula (I) or a form thereof includes a method of use of a compound of Formula (I) or a form thereof for treating or ameliorating HD a subject in need thereof, comprising administering an effective amount of the compound of Formula (I) or a form thereof to the subject, selected from the group consisting of:
  • a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.
  • the compound of Formula (I) or a form thereof includes a compound selected from the group consisting of:
  • a form of the compound is selected from the group consisting of a prodrug, salt, hydrate, solvate, clathrate, isotopologue, racemate, enantiomer, diastereomer, stereoisomer, polymorph and tautomer form thereof.
  • Another embodiment of the use of a compound of Formula (I) or a form thereof includes a method of use of a compound of Formula (I) or a form thereof for treating or ameliorating HD in a subject in need thereof, comprising administering an effective amount of the compound of Formula (I) or a form thereof (wherein compound number (#*) indicates that the salt form was isolated) to the subject, selected from the group consisting of:

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PCT/US2016/066042 2015-12-10 2016-12-11 Methods for treatng huntington's disease Ceased WO2017100726A1 (en)

Priority Applications (29)

Application Number Priority Date Filing Date Title
EP21158464.4A EP3848035B1 (en) 2015-12-10 2016-12-11 1,4-disubstituted pyridazine compounds for treating huntington's disease
KR1020187016467A KR102488323B1 (ko) 2015-12-10 2016-12-11 헌팅턴병 치료 또는 개선을 위한 조성물
PL16874024T PL3386511T3 (pl) 2015-12-10 2016-12-11 Sposoby leczenia choroby huntingtona
IL294124A IL294124B2 (en) 2015-12-10 2016-12-11 Methods for treating huntington's disease
SI201631243T SI3386511T1 (sl) 2015-12-10 2016-12-11 Postopki za zdravljenje Huntingtonove bolezni
EA201800367A EA201800367A1 (ru) 2015-12-10 2016-12-11 Способы лечения болезни хантингтона
CN201680081666.1A CN108697709A (zh) 2015-12-10 2016-12-11 用于治疗亨廷顿病的方法
CN201911286032.1A CN110946865B (zh) 2015-12-10 2016-12-11 用于治疗亨廷顿病的方法
EP16874024.9A EP3386511B2 (en) 2015-12-10 2016-12-11 Methods for treating huntington's disease
NZ743147A NZ743147B2 (en) 2015-12-10 2016-12-11 Methods for treating huntington's disease
CN202110932557.9A CN113717154B (zh) 2015-12-10 2016-12-11 用于治疗亨廷顿病的方法
DK16874024.9T DK3386511T3 (da) 2015-12-10 2016-12-11 Fremgangsmåder til behandling af huntingtons sygdom
LTEP16874024.9T LT3386511T (lt) 2015-12-10 2016-12-11 Hantingtono ligos gydymo būdai
SG11201804915RA SG11201804915RA (en) 2015-12-10 2016-12-11 Methods for treating huntington's disease
AU2016366694A AU2016366694C1 (en) 2015-12-10 2016-12-11 Methods for treating huntington's disease
MX2021001091A MX391850B (es) 2015-12-10 2016-12-11 Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington
ES16874024T ES2879995T3 (es) 2015-12-10 2016-12-11 Métodos para el tratamiento de la enfermedad de Huntington
MX2018007022A MX382671B (es) 2015-12-10 2016-12-11 Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington
JP2018529967A JP2019500352A (ja) 2015-12-10 2016-12-11 ハンチントン病の治療方法
KR1020227021757A KR20220100719A (ko) 2015-12-10 2016-12-11 헌팅턴병 치료 또는 개선을 위한 조성물
US15/781,303 US10874672B2 (en) 2015-12-10 2016-12-11 Methods for treating Huntington's disease
CA3007412A CA3007412C (en) 2015-12-10 2016-12-11 The use of 1,4-disubstituted pyridazine compounds to treat huntington's disease
IL281633A IL281633B (en) 2015-12-10 2016-12-11 Methods for treating huntington's disease
IL259843A IL259843B (en) 2015-12-10 2018-06-06 Substituted monocyclic heteroaryl compounds for use in a method of treating or ameliorating huntington’s disease
PH12018501226A PH12018501226A1 (en) 2015-12-10 2018-06-07 Methods for treating huntingtons disease
US16/710,515 US10881658B2 (en) 2015-12-10 2019-12-11 Methods for treating Huntington's disease
AU2020201380A AU2020201380B2 (en) 2015-12-10 2020-02-25 Methods for treating Huntington's disease
US17/093,194 US11638706B2 (en) 2015-12-10 2020-11-09 Methods for treating Huntington's disease
US18/111,421 US20230201200A1 (en) 2015-12-10 2023-02-17 Methods for Treating Huntington’s Disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562265652P 2015-12-10 2015-12-10
US62/265,652 2015-12-10

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US15/781,303 A-371-Of-International US10874672B2 (en) 2015-12-10 2016-12-11 Methods for treating Huntington's disease
US16/710,515 Division US10881658B2 (en) 2015-12-10 2019-12-11 Methods for treating Huntington's disease

Publications (2)

Publication Number Publication Date
WO2017100726A1 true WO2017100726A1 (en) 2017-06-15
WO2017100726A8 WO2017100726A8 (en) 2018-07-05

Family

ID=59013375

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/066042 Ceased WO2017100726A1 (en) 2015-12-10 2016-12-11 Methods for treatng huntington's disease

Country Status (20)

Country Link
US (4) US10874672B2 (enExample)
EP (2) EP3848035B1 (enExample)
JP (4) JP2019500352A (enExample)
KR (2) KR20220100719A (enExample)
CN (4) CN113717154B (enExample)
AU (2) AU2016366694C1 (enExample)
CA (2) CA3119019C (enExample)
DK (1) DK3386511T3 (enExample)
EA (1) EA201800367A1 (enExample)
ES (1) ES2879995T3 (enExample)
HU (1) HUE055031T2 (enExample)
IL (3) IL294124B2 (enExample)
LT (1) LT3386511T (enExample)
MX (2) MX391850B (enExample)
PH (1) PH12018501226A1 (enExample)
PL (1) PL3386511T3 (enExample)
PT (1) PT3386511T (enExample)
SG (1) SG11201804915RA (enExample)
SI (1) SI3386511T1 (enExample)
WO (1) WO2017100726A1 (enExample)

Cited By (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019005993A1 (en) * 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. METHODS OF TREATING HUNTINGTON'S DISEASE
WO2019028440A1 (en) 2017-08-04 2019-02-07 Skyhawk Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MODULATING SPLICING
WO2019191229A1 (en) * 2018-03-27 2019-10-03 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
WO2019199972A1 (en) * 2018-04-10 2019-10-17 Skyhawk Therapeutics, Inc. Compounds for the treatment of cancer
WO2020005877A1 (en) * 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
WO2020005882A1 (en) * 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
WO2020005873A1 (en) * 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heterocyclic and heteroaryl compounds for treating huntington's disease
WO2020163409A1 (en) * 2019-02-05 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
WO2020163375A1 (en) * 2019-02-04 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
WO2020163406A1 (en) * 2019-02-05 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
WO2020163647A1 (en) * 2019-02-06 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
WO2020163323A1 (en) * 2019-02-04 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
WO2020163544A1 (en) * 2019-02-06 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
WO2020163405A1 (en) * 2019-02-05 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
WO2020163541A1 (en) * 2019-02-05 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
WO2020163401A1 (en) * 2019-02-05 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
WO2020190793A1 (en) * 2019-03-15 2020-09-24 Skyhawk Therapeutics, Inc. Compositions and methods for correction of aberrant splicing
WO2020231977A1 (en) * 2019-05-13 2020-11-19 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
WO2020234715A1 (en) * 2019-05-17 2020-11-26 Novartis Ag Nlrp3 inflammasome inhibitors
US10874672B2 (en) 2015-12-10 2020-12-29 Ptc Therapeutics, Inc. Methods for treating Huntington's disease
WO2021014428A1 (en) 2019-07-25 2021-01-28 Novartis Ag Regulatable expression systems
WO2021084495A1 (en) 2019-11-01 2021-05-06 Novartis Ag The use of a splicing modulator for a treatment slowing progression of huntington's disease
JP2021513519A (ja) * 2018-02-02 2021-05-27 ヴァンダービルト ユニバーシティー ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト
WO2021174165A1 (en) 2020-02-28 2021-09-02 Remix Therapeutics Inc. Heterocyclic amides and their use for modulating splicing
WO2021174176A1 (en) 2020-02-28 2021-09-02 Remix Therapeutics Inc. Pyridazine dervatives for modulating nucleic acid splicing
WO2021174174A1 (en) 2020-02-28 2021-09-02 Remix Therapeutics Inc. Thiophenyl derivatives useful for modulating nucleic acid splicing
WO2021174167A1 (en) 2020-02-28 2021-09-02 Remix Therapeutics Inc. Compounds and methods for modulating splicing
US11129829B2 (en) 2019-06-17 2021-09-28 Skyhawk Therapeutics, Inc. Methods for modulating splicing
WO2021207530A1 (en) 2020-04-08 2021-10-14 Remix Therapeutics Inc. Compounds and methods for modulating splicing
WO2021207554A1 (en) 2020-04-08 2021-10-14 Remix Therapeutics Inc. Compounds and methods for modulating splicing
WO2021260609A1 (en) * 2020-06-25 2021-12-30 Novartis Ag Process for the manufacture of 1,4-disubstituted pyridazine compounds
WO2022006543A1 (en) 2020-07-02 2022-01-06 Remix Therapeutics Inc. 5-[5-(piperidin-4-yl)thieno[3,2-c]pyrazol-2-yl]indazole derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases
WO2022006550A1 (en) 2020-07-02 2022-01-06 Remix Therapeutics Inc. 2-(indazol-5-yl)-6-(piperidin-4-yl)-1,7-naphthyridine derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases
CN114007611A (zh) * 2019-02-04 2022-02-01 斯基霍克疗法公司 用于调节剪接的方法和组合物
WO2022060943A1 (en) * 2020-09-16 2022-03-24 Skyhawk Therapeutics, Inc. Compositions for modulating splicing
WO2022103980A1 (en) 2020-11-12 2022-05-19 Ptc Therapeutics Inc. Novel rna transcript
US11382918B2 (en) 2017-06-28 2022-07-12 Ptc Therapeutics, Inc. Methods for treating Huntington's Disease
US11407753B2 (en) 2017-06-05 2022-08-09 Ptc Therapeutics, Inc. Compounds for treating Huntington's disease
WO2023034811A1 (en) 2021-08-30 2023-03-09 Remix Therapeutics Inc. Compounds and methods for modulating splicing
WO2023034833A1 (en) 2021-08-30 2023-03-09 Remix Therapeutics Inc. Compounds and methods for modulating splicing
WO2023034827A1 (en) 2021-08-30 2023-03-09 Remix Therapeutics Inc. Compounds and methods for modulating splicing
WO2023034836A1 (en) 2021-08-30 2023-03-09 Remix Therapeutics Inc. Compounds and methods for modulating splicing
WO2023034812A1 (en) 2021-08-30 2023-03-09 Remix Therapeutics Inc. Compounds and methods for modulating splicing
WO2023064879A1 (en) 2021-10-13 2023-04-20 Remix Therapeutics Inc. Compounds and methods for modulating nucleic acid splicing
WO2023064880A1 (en) 2021-10-13 2023-04-20 Remix Therapeutics Inc. Compounds and methods for modulating nucleic acid splicing
WO2023092149A1 (en) * 2021-11-22 2023-05-25 Rgenta Therapeutics, Inc. Heterocyclic substituted 1,3,4-thiadiazole and pyridazine compounds and methods of using the same
US11667651B2 (en) 2017-12-22 2023-06-06 Hibercell, Inc. Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
WO2023133217A1 (en) 2022-01-05 2023-07-13 Remix Therapeutics Inc. 2-(indazol-5-yl)-6-(piperidin-4-yl)-1,7-naphthyridine derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases
WO2023133225A1 (en) 2022-01-05 2023-07-13 Remix Therapeutics Inc. Compounds and methods for modulating splicing
WO2023133229A2 (en) 2022-01-05 2023-07-13 Remix Therapeutics Inc. Compounds and methods for modulating splicing
US11806346B2 (en) 2020-05-13 2023-11-07 Chdi Foundation, Inc. HTT modulators for treating Huntington's disease
US11891369B2 (en) 2016-02-23 2024-02-06 Srx Cardio, Llc Compounds for binding proprotein convertase subtilisin/kexin type 9
US11925637B2 (en) 2015-08-21 2024-03-12 Srx Cardio, Llc Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators and their use
US11945782B2 (en) 2015-08-21 2024-04-02 Srx Cardio, Llc Composition and methods of use of tetrahydroisoquinoline small molecules to bind and modulate PCSK9 protein activity
US11944619B2 (en) 2015-08-21 2024-04-02 Srx Cardio, Llc Phenylalanine small organic compounds to directly modulate PCSK9 protein activity
US12006332B2 (en) 2019-06-17 2024-06-11 Hibercell, Inc. Aminopyrimidine derivatives as phosphatidylinositol phosphate kinase inhibitors
RU2826735C2 (ru) * 2019-05-17 2024-09-16 Новартис Аг Ингибиторы инфламмасомы nlrp3
US12115154B2 (en) 2020-12-16 2024-10-15 Srx Cardio, Llc Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9)
US12168657B2 (en) 2022-03-25 2024-12-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US12168012B2 (en) 2018-07-25 2024-12-17 Novartis Ag NLRP3 inflammasome inhibitors
US12281112B2 (en) 2021-04-07 2025-04-22 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
US12281116B2 (en) 2021-11-17 2025-04-22 Chdi Foundation, Inc. HTT modulators for treating Huntington's disease
US12312351B2 (en) 2022-10-31 2025-05-27 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
WO2025133325A1 (en) 2023-12-21 2025-06-26 Dbv Technologies Immunotherapeutic methods, compounds, and compositions for treating or preventing celiac disease
US12378222B2 (en) 2022-08-03 2025-08-05 Novartis Ag NLRP3 inflammasome inhibitors

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020167624A1 (en) 2019-02-13 2020-08-20 Ptc Therapeutics, Inc. Pyrrolo[2,3-d]pyrimidine compounds for treating familial dysautonomia
WO2020167628A1 (en) 2019-02-13 2020-08-20 Ptc Therapeutics, Inc. Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia
WO2021071983A1 (en) * 2019-10-08 2021-04-15 Skyhawk Therapeutics, Inc. Compounds for modulating splicing
WO2021071984A1 (en) * 2019-10-08 2021-04-15 Skyhawk Therapeutics, Inc. Compounds for modulating splicing
WO2021071981A1 (en) * 2019-10-08 2021-04-15 Skyhawk Therapeutics, Inc. Compounds for modulating splicing
IL297044A (en) * 2020-04-09 2022-12-01 Ptc Therapeutics Inc Compounds for the treatment of Huntington's disease
WO2022060944A1 (en) * 2020-09-16 2022-03-24 Skyhawk Therapeutics, Inc. Compositions for modulating splicing
WO2022135567A1 (zh) * 2020-12-25 2022-06-30 上海拓界生物医药科技有限公司 一类含哒嗪的化合物及其医药用途
JP7707310B2 (ja) * 2021-02-08 2025-07-14 メッドシャイン ディスカバリー インコーポレイテッド 置換されたピリダジンフェノール系誘導体
WO2022181694A1 (ja) 2021-02-25 2022-09-01 三菱パワー株式会社 燃焼器用筒、燃焼器、及びガスタービン
WO2024012551A1 (zh) * 2022-07-14 2024-01-18 南京明德新药研发有限公司 氘取代的哒嗪苯并噻吩化合物及其应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030004164A1 (en) * 2000-12-21 2003-01-02 David Bebbington Pyrazole compounds useful as protein kinase inhibitors
US20120083495A1 (en) * 2006-03-17 2012-04-05 The United States Of America, As Represented By The Secretary, Compounds for the treatment of spinal muscular atrophy and other uses
US20140051672A1 (en) * 2012-08-13 2014-02-20 Atwood Kim Cheung 1,4-disubstituted pyridazine analogs there of and methods for treating smn-deficiency-related conditions
WO2014116845A1 (en) 2013-01-23 2014-07-31 Novartis Ag Thiadiazole analogs thereof and methods for treating smn-deficiency-related-conditions
US20140329825A1 (en) * 2011-11-28 2014-11-06 Novartis Ag Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease
WO2015017589A1 (en) 2013-07-31 2015-02-05 Novartis Ag 1,4-disubstituted pyridazine derivatives and their use for treating smn-deficiency-related conditions

Family Cites Families (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE637271A (enExample) 1963-04-04 1900-01-01
US3558618A (en) 1968-04-01 1971-01-26 Dow Chemical Co Novel 4h-pyrazino(1,2-a)pyrimidine-4-ones
GB1383409A (en) 1972-09-09 1974-02-12 Pfizer Ltd Derivatives of 2-amino- and 4-amino-quinazoline and pharmaceutical compositions containing them
US4122274A (en) 1977-05-25 1978-10-24 Bristol-Myers Company 3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones
JPS56150091A (en) 1980-03-28 1981-11-20 Janssen Pharmaceutica Nv 3-(1-piperidinylalkyl)-4h-pyrido(1,2-a)pyrimidine- 4-one derivative and its manufacture
US4342870A (en) 1980-03-28 1982-08-03 Janssen Pharmaceutica N.V. Novel 3-(1-piperidinylalkyl)-4H-pyrido[1,2-a]pyrimidin-4-one derivatives
JPS5852307A (ja) 1981-09-22 1983-03-28 Hitachi Chem Co Ltd 水分散樹脂組成物
US5089633A (en) 1987-04-28 1992-02-18 Georgia Tech Research Corporation Substituted isocoumarins
US5599816A (en) 1990-05-02 1997-02-04 Abbott Laboratories Quinolizinone type compounds
EP0640083A1 (en) 1992-05-13 1995-03-01 E.I. Du Pont De Nemours And Company Substituted pyrido 1,2-a]pyrimidinone derivatives as fungicides
ES2290951T3 (es) 1993-05-11 2008-02-16 The University Of North Carolina At Chapel Hill Oligonucleotidos antisentido que combaten el corte y empalme aberrante y metodos de uso de los mismos.
EP0871628A1 (en) 1995-06-06 1998-10-21 Abbott Laboratories Quinolizinone type compounds
US5916916A (en) 1996-10-10 1999-06-29 Eli Lilly And Company 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods
US5869500A (en) 1996-12-13 1999-02-09 Hoffmann-La Roche Inc. Pyridone compounds useful in treating Alzheimer's disease
CA2269561C (en) 1998-04-22 2007-06-05 Dainippon Ink And Chemicals, Inc. Naphthalene derivative and liquid crystal composition comprising the same
WO2000017197A1 (en) 1998-09-21 2000-03-30 Biochem Pharma Inc. Quinolizinones as integrin inhibitors
US6214986B1 (en) 1998-10-07 2001-04-10 Isis Pharmaceuticals, Inc. Antisense modulation of bcl-x expression
US6210892B1 (en) 1998-10-07 2001-04-03 Isis Pharmaceuticals, Inc. Alteration of cellular behavior by antisense modulation of mRNA processing
US6172216B1 (en) 1998-10-07 2001-01-09 Isis Pharmaceuticals Inc. Antisense modulation of BCL-X expression
HK1048114A1 (en) 1999-10-28 2003-03-21 基本治疗公司 Drug discharge pump inhibitors
CA2398163C (en) 2000-01-24 2011-02-22 Kinacia Pty Ltd. Therapeutic morpholino-substituted compounds
EP1416972B1 (en) 2000-11-09 2012-02-08 Cold Spring Harbor Laboratory Chimeric molecules to modulate gene expression
US6774134B2 (en) 2000-12-20 2004-08-10 Bristol-Myers Squibb Company Heterocyclic substituted 2-methyl-benzimidazole antiviral agents
CA2665516A1 (en) 2001-04-26 2002-11-07 Daiichi Pharmaceutical Co., Ltd. Drug efflux pump inhibitor
EP1474147B1 (en) 2001-12-07 2010-05-05 Vertex Pharmaceuticals Incorporated Pyrimidine-based compounds useful as gsk-3 inhibitors
GB0205281D0 (en) 2002-03-06 2002-04-17 Novartis Ag Organic compounds
ATE548354T1 (de) 2002-07-24 2012-03-15 Ptc Therapeutics Inc Ureido-substituierte benzoesäureverbindungen und ihre verwendung für die nonsense-suppression und behandlung von erkrankungen
KR20050062575A (ko) * 2002-09-30 2005-06-23 뉴로서치 에이/에스 신규한 1,4-디아자바이사이클로알칸 유도체, 이의 제법 및용도
ATE353899T1 (de) 2002-09-30 2007-03-15 Neurosearch As Neue 1,4-diazabicycloalkanderivate, deren herstellung und verwendung
US20070078144A1 (en) 2003-01-29 2007-04-05 Stockwell Brent R Agents for treating neurodegenerative diseases
AU2004249730A1 (en) 2003-06-20 2004-12-29 Novartis Vaccines And Diagnostics, Inc. Pyridino(1,2-A)pyrimidin-4-one compounds as anticancer agents
GB0315494D0 (en) 2003-07-02 2003-08-06 Biofocus Plc Compounds which bind to the active site of protein kinase enzymes
ZA200600424B (en) 2003-08-01 2007-05-30 Genelabs Tech Inc Bicyclic imidazol derivatives against flaviviridae
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
US20050074801A1 (en) 2003-09-09 2005-04-07 Monia Brett P. Chimeric oligomeric compounds comprising alternating regions of northern and southern conformational geometry
US7655657B2 (en) * 2003-12-22 2010-02-02 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
US20050137203A1 (en) 2003-12-22 2005-06-23 Jianguo Ji 3-quinuclidinyl amino-substituted biaryl derivatives
US7309699B2 (en) 2003-12-22 2007-12-18 Abbott Laboratories 3-Quinuclidinyl amino-substituted biaryl derivatives
US20050245531A1 (en) * 2003-12-22 2005-11-03 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
CN101723949B (zh) 2003-12-24 2013-10-23 生物区科学管理控股有限公司 用于治疗呼吸道合胞体病毒感染的多环试剂
SE0400184D0 (sv) 2004-01-30 2004-01-30 Fyrkloevern Scandinavia Ab New therapeutical use
TW200536830A (en) 2004-02-06 2005-11-16 Chugai Pharmaceutical Co Ltd 1-(2H)-isoquinolone derivative
US20070191374A1 (en) 2004-04-08 2007-08-16 Neurogen Coroperation Substituted cinnolin-4-ylamines
WO2005105801A1 (en) 2004-05-04 2005-11-10 Warner-Lambert Company Llc Pyrrolyl substituted pyrido[2,3-d]pyrimidin-7-ones and derivatives thereof as therapeutic agents
WO2006078834A1 (en) 2005-01-21 2006-07-27 Janssen Pharmaceutica N.V. Novel heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors
US7879992B2 (en) 2005-01-31 2011-02-01 Isis Pharmaceuticals, Inc. Modification of MyD88 splicing using modified oligonucleotides
JP2006219453A (ja) 2005-02-14 2006-08-24 Tokyo Univ Of Pharmacy & Life Science キノリン環を母核とする金属識別型二波長性蛍光分子
US7563601B1 (en) 2005-06-01 2009-07-21 City Of Hope Artificial riboswitch for controlling pre-mRNA splicing
MX2007015675A (es) * 2005-07-04 2008-02-20 Novo Nordisk As Antagonistas del receptor de histamina h3.
US8258109B2 (en) 2005-10-20 2012-09-04 Isis Pharmaceuticals, Inc. Compositions and methods for modulation of LMNA expression
WO2007058894A2 (en) 2005-11-10 2007-05-24 The University Of North Carolina At Chapel Hill Splice switching oligomers for tnf superfamily receptors and their use in treatment of disease
ES2453380T3 (es) 2006-01-26 2014-04-07 Isis Pharmaceuticals, Inc. Composiciones y utilizaciones dirigidas hacia la huntingtina
CA2640058C (en) 2006-01-27 2018-04-24 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for the use in modulation of micrornas
AR059339A1 (es) 2006-02-09 2008-03-26 Chugai Pharmaceutical Co Ltd Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene
WO2007130383A2 (en) * 2006-04-28 2007-11-15 Northwestern University Compositions and treatments using pyridazine compounds and secretases
US20080247964A1 (en) * 2006-05-08 2008-10-09 Yuelian Xu Substituted azaspiro derivatives
TW200812588A (en) 2006-05-15 2008-03-16 Neurogen Corp CRF1 receptor ligands comprising heteroaryl fused bicycles
EP2029607A1 (en) * 2006-05-23 2009-03-04 NeuroSearch A/S Novel 8,10-diaza-bicycloý4.3.1¨decane derivatives and their medical use
ATE469144T1 (de) 2006-07-20 2010-06-15 Amgen Inc Substituierte pyridonverbindungen und anwendungsverfahren
WO2008013997A2 (en) 2006-07-27 2008-01-31 The Trustees Of Columbia University In The City Of New York Fluorescent substrates for monoamine transporters as optical false neurotransmitters
WO2008049864A1 (en) 2006-10-25 2008-05-02 Neurosearch A/S Oxadiazole and thiadiazole compounds and their use as nicotinic acetylcholine receptor modulators
US8314119B2 (en) * 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
CA2673183C (en) 2006-12-22 2014-06-10 Eric Dale Jones Bicyclic pyrimidinones and uses thereof
US20080171792A1 (en) 2006-12-28 2008-07-17 Jobdevairakkam Christopher New Use of highly concentrated formulations of 4-phenylbutyrate for treatment of certain disorders
FR2914188B1 (fr) 2007-03-28 2012-06-22 Trophos Nouvelle composition a base d'oxime de cholest-4-en-3-one
EP2014656A3 (en) * 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC New heteocyclic h3 antagonists
EP2215074B1 (en) 2007-09-27 2014-02-19 The United States of America, as Represented by the Secretary, Department of Health and Human Services Isoindoline compounds for the treatment of spinal muscular atrophy and other uses
ES2548768T3 (es) 2007-09-27 2015-10-20 Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii Imidazolotiadiazoles para su uso como inhibidores de proteína quinasa
US8153813B2 (en) 2007-12-20 2012-04-10 Abbott Laboratories Benzothiazole and benzooxazole derivatives and methods of use
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
US20090258907A1 (en) 2008-04-09 2009-10-15 Abbott Laboratories Compounds useful as inhibitors of rock kinases
WO2009131958A2 (en) 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising triazine derivatives
WO2009151546A2 (en) 2008-05-27 2009-12-17 Ptc Therapeutics, Inc. Methods for treating spinal muscular atrophy
PT2315588E (pt) 2008-06-20 2013-03-25 Rottapharm Spa Derivados de 6-1h-imidazo-quinazolina e quinolinas, novos inibidores de mao e ligandos de receptores de imidazolinas
EP2138493A1 (en) 2008-06-26 2009-12-30 Sanofi-Aventis Substituted pyrimidone derivatives
CN102143962B (zh) 2008-07-02 2015-03-11 爱维艾珂瑟有限公司 具有抗病毒特性的化合物
US8932818B2 (en) 2008-08-13 2015-01-13 Ptc Therapeutics, Inc. Screening assays for compounds that modulate programmed ribosomal frameshifting
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
EP2379564A1 (en) 2008-12-19 2011-10-26 Schering Corporation Bicyclic heterocyclic derivatives and methods of use thereof
JP2012517471A (ja) 2009-02-11 2012-08-02 スノビオン プハルマセウトイカルス インコーポレイテッド ヒスタミンｈ３インバースアゴニスト及びアンタゴニスト、並びにその使用方法
FR2945289A1 (fr) 2009-05-11 2010-11-12 Sanofi Aventis Derives de 2-cycloamino-5-(pyridin-4-yl)imidazo°2,1-b! °1,3,4!thiadiazole, leur preparation et leur application en therapeutique
AU2010262643B2 (en) * 2009-06-19 2015-02-19 Abbvie Inc. Diazahomoadamantane derivatives and methods of use thereof
KR102173836B1 (ko) 2009-09-11 2020-11-05 아이오니스 파마수티컬즈, 인코포레이티드 헌팅틴 발현의 조절
WO2011050245A1 (en) 2009-10-23 2011-04-28 Yangbo Feng Bicyclic heteroaryls as kinase inhibitors
WO2011057204A2 (en) 2009-11-06 2011-05-12 The Johns Hopkins University Lrrk2-mediated neuronal toxicity
WO2011062853A1 (en) 2009-11-20 2011-05-26 Merck Sharp & Dohme Corp. Quinolizidinone carboxamide m1 receptor positive allosteric modulators
EP2523956A1 (en) 2010-01-13 2012-11-21 Institut Pasteur Korea Anti - infective pyrido (1,2 -a) pyrimidines
US20130059902A1 (en) 2010-02-08 2013-03-07 Isis Pharmaceuticals, Inc. Methods and compositions useful in treatment of diseases or conditions related to repeat expansion
AU2011213563B2 (en) 2010-02-08 2015-12-24 Ionis Pharmaceuticals, Inc. Selective reduction of allelic variants
ES2733708T3 (es) 2010-02-08 2019-12-02 Ionis Pharmaceuticals Inc Reducción selectiva de variantes alélicas
WO2011149856A1 (en) 2010-05-24 2011-12-01 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
US20120008349A1 (en) * 2010-07-12 2012-01-12 Scharf Mesa P Power inverter systems with high-accuracy reference signal generation and associated methods of control
EP2595663A4 (en) 2010-07-19 2014-03-05 Isis Pharmaceuticals Inc MODULATION OF DYSTROPHIA MYOTONICA PROTEIN KINASE (DMPK) EXPRESSION
WO2012075393A2 (en) * 2010-12-02 2012-06-07 President And Fellows Of Harvard College Activators of proteasomal degradation and uses thereof
WO2012104823A2 (en) 2011-02-04 2012-08-09 Novartis Ag Pyridopyrimidinone compounds in the treatment of neurodegenerative diseases
WO2012109395A1 (en) 2011-02-08 2012-08-16 Isis Pharmaceuticals, Inc. Oligomeric compounds comprising bicyclic nucleotides and uses thereof
US8703763B2 (en) 2011-03-02 2014-04-22 Hoffmann-La Roche Inc. Bridged piperidine derivatives
WO2013019938A1 (en) 2011-08-02 2013-02-07 The Brigham And Women's Hospital, Inc. Pyridazine derivatives as eaat2 activators
WO2013022967A1 (en) 2011-08-11 2013-02-14 Isis Pharmaceuticals, Inc. Gapped oligomeric compounds comprising 5'-modified deoxyribonucleosides in the gap and uses thereof
US8871756B2 (en) 2011-08-11 2014-10-28 Hoffmann-La Roche Inc. Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease
US20130046093A1 (en) 2011-08-18 2013-02-21 Korea Institute Of Science And Technology Pharmaceutical compositions for preventing or treating degenerative brain disease and method of screening the same
WO2013033223A1 (en) 2011-08-29 2013-03-07 Isis Pharmaceuticals, Inc. Methods and compounds useful in conditions related to repeat expansion
WO2013059606A1 (en) 2011-10-21 2013-04-25 Tufts Medical Center, Inc. Compounds and methods for the treatment of muscular disease, and related screening methods
GB201119538D0 (en) 2011-11-10 2011-12-21 Viral Ltd Pharmaceutical compounds
WO2013101974A1 (en) 2011-12-30 2013-07-04 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy
JP6193888B2 (ja) 2012-01-26 2017-09-06 ピーティーシー セラピューティクス， インコーポレイテッド 脊髄性筋萎縮症を治療するための化合物
NZ628186A (en) 2012-02-10 2016-03-31 Ptc Therapeutics Inc Compounds for treating spinal muscular atrophy
WO2013130689A1 (en) 2012-03-01 2013-09-06 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy
CN104470909B (zh) 2012-03-23 2018-04-24 Ptc医疗公司 用于治疗脊髓性肌萎缩的化合物
RS58043B1 (sr) 2012-04-24 2019-02-28 Vertex Pharma Inhibitori dna-pk
US8980934B2 (en) * 2012-06-22 2015-03-17 University Health Network Kinase inhibitors and method of treating cancer with same
US9212209B2 (en) 2012-07-13 2015-12-15 Indiana University Research And Technology Corporation Screening methods for spinal muscular atrophy
US20150275208A1 (en) 2012-10-12 2015-10-01 Isis Pharmaceuticals, Inc. Selective antisense compounds and uses thereof
EP2906255B1 (en) 2012-10-12 2023-02-22 Ionis Pharmaceuticals, Inc. Antisense compounds and uses thereof
US9227976B2 (en) 2012-10-25 2016-01-05 Usher Iii Initiative, Inc. Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
EP2951304B1 (en) 2013-02-04 2020-07-08 Ionis Pharmaceuticals, Inc. Selective antisense compounds and uses thereof
EP2964649B1 (en) 2013-03-05 2017-05-10 Merck Patent GmbH Triazolo[4,5-d]pyrimidine derivatives for the treatment of diseases such as cancer
CA2910508A1 (en) 2013-05-14 2014-11-20 Song Feng Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection
CA2913785C (en) 2013-06-25 2021-08-31 F. Hoffmann-La Roche Ag Compounds for treating spinal muscular atrophy
BR112015032718A2 (pt) 2013-08-19 2019-09-17 Hoffmann La Roche composto de modificação de splicing do gene foxm1, uso do composto, formulação farmacêutica e métodos de triagem de compostos
WO2015095449A1 (en) 2013-12-19 2015-06-25 Ptc Therapeutics, Inc. Methods for modulating the amount rna transcripts
WO2015095446A1 (en) 2013-12-19 2015-06-25 Ptc Therapeutics, Inc. Methods for modulating the amount of rna transcripts
EP3082820B1 (en) 2013-12-19 2022-07-20 PTC Therapeutics, Inc. Methods for modulating the amount of rna transcripts
RU2016133035A (ru) 2014-01-16 2018-02-21 Уэйв Лайф Сайенсес Лтд. Хиральный дизайн
WO2015107494A1 (en) 2014-01-17 2015-07-23 Novartis Ag 1 -(triazin-3-yi_/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2
AR099134A1 (es) 2014-01-24 2016-06-29 Hoffmann La Roche Procedimiento para la preparación de n-[(3-aminooxetán-3-il)metil]-2-(1,1-dioxo-3,5-dihidro-1,4-benzotiazepín-4-il)-6-metil-quinazolín-4-amina
TWI674257B (zh) 2014-03-14 2019-10-11 日商拉夸里亞創藥股份有限公司 作為ｔｒｐｍ８拮抗劑之氮雜螺衍生物
PL3663296T3 (pl) 2014-05-15 2023-08-07 F. Hoffmann-La Roche Ag Sposób wytwarzania związków użytecznych w leczeniu rdzeniowego zaniku mięśni
GB201410693D0 (en) 2014-06-16 2014-07-30 Univ Southampton Splicing modulation
WO2015195811A2 (en) 2014-06-17 2015-12-23 Novozymes A/S Biological phosphorus removal from wastewater
CN106459067B (zh) 2014-06-25 2019-05-31 豪夫迈·罗氏有限公司 用于治疗脊髓性肌萎缩的咪唑并[1，2-a]吡嗪-1基苯甲酰胺化合物
LT3237618T (lt) 2014-12-24 2019-07-10 Uniqure Ip B.V. Rnri sukeltas hantingtino geno slopinimas
WO2016115434A1 (en) 2015-01-16 2016-07-21 The General Hospital Corporation Compounds for improving mrna splicing
WO2016128343A1 (en) 2015-02-09 2016-08-18 F. Hoffmann-La Roche Ag Compounds for the treatment of cancer
GB201502567D0 (en) 2015-02-16 2015-04-01 Sentinel Oncology Ltd Pharmaceutical compounds
GB201506933D0 (en) 2015-04-23 2015-06-10 Sentinel Oncology Ltd Pharmaceutical compounds
CN107635999B (zh) 2015-05-20 2020-09-25 豪夫迈·罗氏有限公司 用于治疗脊髓性肌萎缩的化合物
EP3310169B1 (en) 2015-05-30 2023-05-17 PTC Therapeutics, Inc. Methods for modulating rna splicing
MA43072A (fr) 2015-07-22 2018-05-30 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
WO2017023987A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
AU2016353961B2 (en) 2015-11-12 2019-08-29 F. Hoffmann-La Roche Ag Compositions for treating spinal muscular atrophy
CN108137601A (zh) 2015-11-12 2018-06-08 豪夫迈·罗氏有限公司 用于治疗肌萎缩性侧索硬化症的化合物
EP3386978B1 (en) 2015-12-10 2021-01-27 H. Hoffnabb-La Roche Ag Bridged piperidine derivatives
KR20220100719A (ko) * 2015-12-10 2022-07-15 피티씨 테라퓨틱스, 인크. 헌팅턴병 치료 또는 개선을 위한 조성물
US10526345B2 (en) 2016-04-08 2020-01-07 Mankind Pharma Ltd. Compounds as GPR119 agonists
AR108325A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
MA45270A (fr) 2016-05-04 2017-11-09 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
JP7044375B2 (ja) 2016-05-31 2022-03-30 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｐｔｐｎ１１の複素環式阻害剤
WO2018022473A1 (en) 2016-07-25 2018-02-01 Wave Life Sciences Ltd. Phasing
TWI848901B (zh) 2016-10-24 2024-07-21 美商傳達治療有限公司 Shp2磷酸酶抑制劑及其使用方法
EP3606562A4 (en) 2017-04-03 2020-11-11 Acceleron Pharma Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF SPINAL AMYOTROPHIA
US11591336B2 (en) 2017-05-26 2023-02-28 D. E. Shaw Research, Llc Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors
EP4151627A1 (en) 2017-06-05 2023-03-22 PTC Therapeutics, Inc. Compounds for treating huntington's disease
EP3644996B1 (en) 2017-06-28 2023-07-26 PTC Therapeutics, Inc. Methods for treating huntington's disease
BR112019027719A2 (pt) 2017-06-28 2020-07-28 Ptc Therapeutics, Inc. métodos para tratar a doença de huntington
JP7312749B2 (ja) 2017-08-04 2023-07-21 スカイホーク・セラピューティクス・インコーポレーテッド スプライシングをモジュレートする方法および組成物
EP3755699A1 (en) 2018-02-21 2020-12-30 Relay Therapeutics, Inc. Shp2 phosphatase inhibitors and methods of use thereof
US12138263B2 (en) 2018-03-21 2024-11-12 Relay Therapeutics, Inc. Pyrazolo[3,4-b]pyrazine SHP2 phosphatase inhibitors and methods of use thereof
MX2020009782A (es) 2018-03-21 2021-01-20 Relay Therapeutics Inc Inhibidores de la fosfatasa shp2 y métodos para su uso.
JP7399870B2 (ja) 2018-03-27 2023-12-18 ピーティーシー セラピューティクス， インコーポレイテッド ハンチントン病を処置するための化合物
US11685746B2 (en) 2018-06-27 2023-06-27 Ptc Therapeutics, Inc. Heteroaryl compounds for treating Huntington's disease
CN112805280B (zh) 2018-06-27 2024-12-06 Ptc医疗公司 用于治疗亨廷顿氏病的杂芳基化合物
LT3814357T (lt) 2018-06-27 2024-06-25 Ptc Therapeutics, Inc. Heterocikliniai ir heteroarilų junginiai, skirti hantingtono ligos gydymui
EP3969446B1 (en) 2019-05-13 2023-09-27 PTC Therapeutics, Inc. Compounds for treating huntington's disease
WO2021007378A1 (en) 2019-07-11 2021-01-14 Ptc Therapeutics, Inc. Compounds for use in treating huntington's disease
JP2023500251A (ja) 2019-11-01 2023-01-05 ノバルティス アーゲー ハンチントン病の進行を遅らせる処置のためのスプライシングモジュレーターの使用

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030004164A1 (en) * 2000-12-21 2003-01-02 David Bebbington Pyrazole compounds useful as protein kinase inhibitors
US20120083495A1 (en) * 2006-03-17 2012-04-05 The United States Of America, As Represented By The Secretary, Compounds for the treatment of spinal muscular atrophy and other uses
US20140329825A1 (en) * 2011-11-28 2014-11-06 Novartis Ag Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease
US20140051672A1 (en) * 2012-08-13 2014-02-20 Atwood Kim Cheung 1,4-disubstituted pyridazine analogs there of and methods for treating smn-deficiency-related conditions
WO2014028459A1 (en) 2012-08-13 2014-02-20 Novartis Ag 1,4-disubstituted pyridazine analogs and methods for treating smn-deficiency-related conditions
WO2014116845A1 (en) 2013-01-23 2014-07-31 Novartis Ag Thiadiazole analogs thereof and methods for treating smn-deficiency-related-conditions
WO2015017589A1 (en) 2013-07-31 2015-02-05 Novartis Ag 1,4-disubstituted pyridazine derivatives and their use for treating smn-deficiency-related conditions

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
"Bioreversible Carriers in Drug Design", 1987, AMERICAN PHARMACEUTICAL ASSOCIATION AND PERGAMON PRESS
ANDERSON ET AL.: "The Practice of Medicinal Chemistry", 1996, ACADEMIC PRESS
MACDONALD ET AL.: "Quantification Assays for Total and Polyglutamine-Expanded Huntingtin Proteins", PLOS ONE, vol. 9, no. 5, 2014, pages 1 - 17, XP055390961 *
P. GOULD, INTERNATIONAL J. OF PHARMACEUTICS, vol. 33, 1986, pages 201 - 217
P. STAHL ET AL.: "Handbook ofPharmaceutical Salts. Properties, Selection and Use", 2002, WILEY-VCH
PRYOR ET AL.: "Huntingtin promotes mTORC1 signaling in the pathogenesis of Huntington's disease", SCI.SIGNAL., vol. 7, no. Issue 349, 2014, pages 1 - 12, XP009507194 *
S. BERGE, JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 66, no. 1, 1977, pages 1 - 19
T. HIGUCHIW. STELLA: "Pro-drugs as Novel Delivery Systems", A.C.S. SYMPOSIUM SERIES, vol. 14
T.W. GREENE ET AL.: "Protective Groups in organic Synthesis", 1991, WILEY

Cited By (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11944619B2 (en) 2015-08-21 2024-04-02 Srx Cardio, Llc Phenylalanine small organic compounds to directly modulate PCSK9 protein activity
US11925637B2 (en) 2015-08-21 2024-03-12 Srx Cardio, Llc Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators and their use
US11945782B2 (en) 2015-08-21 2024-04-02 Srx Cardio, Llc Composition and methods of use of tetrahydroisoquinoline small molecules to bind and modulate PCSK9 protein activity
US10874672B2 (en) 2015-12-10 2020-12-29 Ptc Therapeutics, Inc. Methods for treating Huntington's disease
US11638706B2 (en) 2015-12-10 2023-05-02 Ptc Therapeutics, Inc. Methods for treating Huntington's disease
US10881658B2 (en) 2015-12-10 2021-01-05 Ptc Therapeutics, Inc. Methods for treating Huntington's disease
US11891369B2 (en) 2016-02-23 2024-02-06 Srx Cardio, Llc Compounds for binding proprotein convertase subtilisin/kexin type 9
US12384789B2 (en) 2017-06-05 2025-08-12 Ptc Therapeutics, Inc. Compounds for treating Huntington's disease
US11407753B2 (en) 2017-06-05 2022-08-09 Ptc Therapeutics, Inc. Compounds for treating Huntington's disease
CN111163838B (zh) * 2017-06-28 2023-03-28 Ptc医疗公司 用于治疗亨廷顿氏病的方法
US11395822B2 (en) 2017-06-28 2022-07-26 Ptc Therapeutics, Inc. Methods for treating Huntington's disease
CN111163838A (zh) * 2017-06-28 2020-05-15 Ptc医疗公司 用于治疗亨廷顿氏病的方法
WO2019005993A1 (en) * 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. METHODS OF TREATING HUNTINGTON'S DISEASE
US11382918B2 (en) 2017-06-28 2022-07-12 Ptc Therapeutics, Inc. Methods for treating Huntington's Disease
US11091475B2 (en) 2017-08-04 2021-08-17 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
GB2579747B (en) * 2017-08-04 2022-06-08 Skyhawk Therapeutics Inc Methods and compositions for modulating splicing
EP3689863A1 (en) * 2017-08-04 2020-08-05 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
CN111194215B (zh) * 2017-08-04 2024-03-01 斯基霍克疗法公司 用于调节剪接的方法和组合物
KR102636383B1 (ko) 2017-08-04 2024-02-14 스카이호크 테라퓨틱스, 인코포레이티드 스플라이싱을 조절하는 방법 및 조성물
KR102636384B1 (ko) 2017-08-04 2024-02-14 스카이호크 테라퓨틱스, 인코포레이티드 스플라이싱을 조절하는 방법 및 조성물
GB2579747A (en) * 2017-08-04 2020-07-01 Skyhawk Therapeutics Inc Methods and compositions for modulating splicing
CN111499615B (zh) * 2017-08-04 2024-02-02 斯基霍克疗法公司 用于调节剪接的方法和组合物
CN111194215A (zh) * 2017-08-04 2020-05-22 斯基霍克疗法公司 用于调节剪接的方法和组合物
US11326165B1 (en) 2017-08-04 2022-05-10 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
GB2587457B (en) * 2017-08-04 2022-06-01 Skyhawk Therapeutics Inc Methods and compositions for modulating splicing
JP2020169171A (ja) * 2017-08-04 2020-10-15 スカイホーク・セラピューティクス・インコーポレーテッド スプライシングをモジュレートする方法および組成物
JP2020530487A (ja) * 2017-08-04 2020-10-22 スカイホーク・セラピューティクス・インコーポレーテッド スプライシングをモジュレートする方法および組成物
US11162101B2 (en) 2017-08-04 2021-11-02 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
JP7312749B2 (ja) 2017-08-04 2023-07-21 スカイホーク・セラピューティクス・インコーポレーテッド スプライシングをモジュレートする方法および組成物
WO2019028440A1 (en) 2017-08-04 2019-02-07 Skyhawk Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MODULATING SPLICING
KR20200038545A (ko) * 2017-08-04 2020-04-13 스카이호크 테라퓨틱스, 인코포레이티드 스플라이싱을 조절하는 방법 및 조성물
KR20200037844A (ko) * 2017-08-04 2020-04-09 스카이호크 테라퓨틱스, 인코포레이티드 스플라이싱을 조절하는 방법 및 조성물
IL272413B (en) * 2017-08-04 2022-09-01 Skyhawk Therapeutics Inc Methods and compositions for modulating splicing
EP3661509A4 (en) * 2017-08-04 2021-01-13 Skyhawk Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MODULATING THE SPLICE
IL273741B (en) * 2017-08-04 2022-09-01 Skyhawk Therapeutics Inc Methods and compositions for modulating splicing
CN111499615A (zh) * 2017-08-04 2020-08-07 斯基霍克疗法公司 用于调节剪接的方法和组合物
GB2587457A (en) * 2017-08-04 2021-03-31 Skyhawk Therapeutics Inc Methods and compositions for modulating splicing
US11434489B1 (en) 2017-08-04 2022-09-06 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
JP7135026B2 (ja) 2017-08-04 2022-09-12 スカイホーク・セラピューティクス・インコーポレーテッド スプライシングをモジュレートする方法および組成物
US11008572B2 (en) 2017-08-04 2021-05-18 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
US11603531B1 (en) 2017-08-04 2023-03-14 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
US11021708B2 (en) 2017-08-04 2021-06-01 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
US11667651B2 (en) 2017-12-22 2023-06-06 Hibercell, Inc. Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
JP7352294B2 (ja) 2018-02-02 2023-09-28 ヴァンダービルト ユニバーシティー ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト
JP2021513519A (ja) * 2018-02-02 2021-05-27 ヴァンダービルト ユニバーシティー ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト
CN112135815A (zh) * 2018-03-27 2020-12-25 Ptc医疗公司 用于治疗亨廷顿氏病的化合物
US12103926B2 (en) 2018-03-27 2024-10-01 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
CN112203653A (zh) * 2018-03-27 2021-01-08 Ptc医疗公司 用于治疗亨廷顿氏病的化合物
WO2019191092A1 (en) * 2018-03-27 2019-10-03 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
WO2019191229A1 (en) * 2018-03-27 2019-10-03 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
JP2021519291A (ja) * 2018-03-27 2021-08-10 ピーティーシー セラピューティクス， インコーポレイテッド ハンチントン病を処置するための化合物
US11780839B2 (en) 2018-03-27 2023-10-10 Ptc Therapeutics, Inc. Compounds for treating Huntington's disease
JP7399869B2 (ja) 2018-03-27 2023-12-18 ピーティーシー セラピューティクス， インコーポレイテッド ハンチントン病を処置するための化合物
EP3773552A4 (en) * 2018-03-27 2022-01-26 PTC Therapeutics, Inc. COMPOUNDS FOR THE TREATMENT OF HUNTINGTON'S DISEASE
WO2019199972A1 (en) * 2018-04-10 2019-10-17 Skyhawk Therapeutics, Inc. Compounds for the treatment of cancer
CN112272666A (zh) * 2018-04-10 2021-01-26 斯基霍克疗法公司 用于治疗癌症的化合物
US11530207B2 (en) 2018-04-10 2022-12-20 Skyhawk Therapeutics, Inc. Compounds for the treatment of cancer
JP7421507B2 (ja) 2018-06-27 2024-01-24 ピーティーシー セラピューティクス， インコーポレイテッド ハンチントン病を処置するためのヘテロ環式およびヘテロアリール化合物
AU2019294478B2 (en) * 2018-06-27 2023-03-23 Ptc Therapeutics, Inc. Heterocyclic and heteroaryl compounds for treating Huntington's disease
US11858941B2 (en) 2018-06-27 2024-01-02 Ptc Therapeutics, Inc. Heterocyclic and heteroaryl compounds for treating Huntington's disease
WO2020005882A1 (en) * 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
US11685746B2 (en) 2018-06-27 2023-06-27 Ptc Therapeutics, Inc. Heteroaryl compounds for treating Huntington's disease
JP2021528466A (ja) * 2018-06-27 2021-10-21 ピーティーシー セラピューティクス， インコーポレイテッド ハンチントン病を処置するためのヘテロアリール化合物
CN112654625A (zh) * 2018-06-27 2021-04-13 Ptc医疗公司 用于治疗亨廷顿氏病的杂环和杂芳基化合物
WO2020005877A1 (en) * 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
EP4434990A1 (en) * 2018-06-27 2024-09-25 PTC Therapeutics, Inc. Heterocyclic and heteroaryl compounds for treating huntington's disease
JP2021528467A (ja) * 2018-06-27 2021-10-21 ピーティーシー セラピューティクス， インコーポレイテッド ハンチントン病を処置するためのヘテロ環式およびヘテロアリール化合物
IL279688B2 (en) * 2018-06-27 2025-01-01 Ptc Therapeutics Inc Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease
US12139499B2 (en) 2018-06-27 2024-11-12 Ptc Therapeutics, Inc. Heteroaryl compounds for treating Huntington's disease
AU2023203241B2 (en) * 2018-06-27 2025-01-02 Ptc Therapeutics, Inc. Heterocyclic and heteroaryl compounds for treating Huntington's disease
WO2020005873A1 (en) * 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heterocyclic and heteroaryl compounds for treating huntington's disease
JP7515415B2 (ja) 2018-06-27 2024-07-12 ピーティーシー セラピューティクス， インコーポレイテッド ハンチントン病を処置するためのヘテロアリール化合物
IL279688B1 (en) * 2018-06-27 2024-09-01 Ptc Therapeutics Inc Heterocyclic and heteroaryl compounds for treating huntington's disease
US12168012B2 (en) 2018-07-25 2024-12-17 Novartis Ag NLRP3 inflammasome inhibitors
WO2020163375A1 (en) * 2019-02-04 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
CN114007611A (zh) * 2019-02-04 2022-02-01 斯基霍克疗法公司 用于调节剪接的方法和组合物
WO2020163323A1 (en) * 2019-02-04 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
CN113660936A (zh) * 2019-02-04 2021-11-16 斯基霍克疗法公司 用于调节剪接的方法和组合物
WO2020163406A1 (en) * 2019-02-05 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
CN114126613A (zh) * 2019-02-05 2022-03-01 斯基霍克疗法公司 用于调节剪接的方法和组合物
WO2020163401A1 (en) * 2019-02-05 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
US11845744B2 (en) 2019-02-05 2023-12-19 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
CN113645970A (zh) * 2019-02-05 2021-11-12 斯基霍克疗法公司 用于调节剪接的方法和组合物
JP7603592B2 (ja) 2019-02-05 2024-12-20 スカイホーク・セラピューティクス・インコーポレーテッド スプライシングを調節するための方法および組成物
WO2020163541A1 (en) * 2019-02-05 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
JP2022521467A (ja) * 2019-02-05 2022-04-08 スカイホーク・セラピューティクス・インコーポレーテッド スプライシングを調節するための方法および組成物
EP3920920A4 (en) * 2019-02-05 2022-09-28 Skyhawk Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MODULATING SPLICE
EP3920915A4 (en) * 2019-02-05 2022-10-05 Skyhawk Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MODULATING SPLICE
WO2020163405A1 (en) * 2019-02-05 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
US20230020922A1 (en) * 2019-02-05 2023-01-19 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
EP3920919A4 (en) * 2019-02-05 2023-03-29 Skyhawk Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MODULATING SPLICE
WO2020163409A1 (en) * 2019-02-05 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
US11964971B2 (en) 2019-02-06 2024-04-23 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
WO2020163647A1 (en) * 2019-02-06 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
US20230054781A1 (en) * 2019-02-06 2023-02-23 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
WO2020163544A1 (en) * 2019-02-06 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
CN113840602A (zh) * 2019-03-15 2021-12-24 斯基霍克疗法公司 用于校正异常剪接的组合物和方法
WO2020190793A1 (en) * 2019-03-15 2020-09-24 Skyhawk Therapeutics, Inc. Compositions and methods for correction of aberrant splicing
WO2020231977A1 (en) * 2019-05-13 2020-11-19 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
EP4219466A1 (en) * 2019-05-13 2023-08-02 PTC Therapeutics, Inc. Compunds for treating huntington's disease
JP2022533120A (ja) * 2019-05-13 2022-07-21 ピーティーシー セラピューティクス， インコーポレイテッド ハンチントン病を処置するための化合物
JP7649257B2 (ja) 2019-05-13 2025-03-19 ピーティーシー セラピューティクス， インコーポレイテッド ハンチントン病を処置するための化合物
US20220204478A1 (en) * 2019-05-13 2022-06-30 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
IL287945B1 (en) * 2019-05-13 2025-11-01 Ptc Therapeutics Inc Compounds for the treatment of Huntington's disease
US11254653B2 (en) 2019-05-17 2022-02-22 Novartis Ag NLRP3 inflammasome inhibitors
US11208399B2 (en) 2019-05-17 2021-12-28 Novartis Ag NLRP3 inflammasome inhibitors
RU2826735C2 (ru) * 2019-05-17 2024-09-16 Новартис Аг Ингибиторы инфламмасомы nlrp3
US12139471B2 (en) 2019-05-17 2024-11-12 Novartis Ag NLRP3 inflammasome inhibitors
WO2020234715A1 (en) * 2019-05-17 2020-11-26 Novartis Ag Nlrp3 inflammasome inhibitors
TWI874398B (zh) * 2019-05-17 2025-03-01 瑞士商諾華公司 Nlrp3炎性小體抑制劑
CN114269922A (zh) * 2019-06-17 2022-04-01 斯基霍克疗法公司 用于调节剪接的方法
US11129829B2 (en) 2019-06-17 2021-09-28 Skyhawk Therapeutics, Inc. Methods for modulating splicing
US12006332B2 (en) 2019-06-17 2024-06-11 Hibercell, Inc. Aminopyrimidine derivatives as phosphatidylinositol phosphate kinase inhibitors
WO2021014428A1 (en) 2019-07-25 2021-01-28 Novartis Ag Regulatable expression systems
WO2021084495A1 (en) 2019-11-01 2021-05-06 Novartis Ag The use of a splicing modulator for a treatment slowing progression of huntington's disease
WO2021174167A1 (en) 2020-02-28 2021-09-02 Remix Therapeutics Inc. Compounds and methods for modulating splicing
WO2021174174A1 (en) 2020-02-28 2021-09-02 Remix Therapeutics Inc. Thiophenyl derivatives useful for modulating nucleic acid splicing
WO2021174176A1 (en) 2020-02-28 2021-09-02 Remix Therapeutics Inc. Pyridazine dervatives for modulating nucleic acid splicing
WO2021174163A1 (en) 2020-02-28 2021-09-02 Remix Therapeutics Inc. Fused bicyclic compounds useful for modulating nucleic acid splicing
WO2021174164A1 (en) 2020-02-28 2021-09-02 Remix Therapeutics Inc. Compounds and methods for modulating splicing
WO2021174170A1 (en) 2020-02-28 2021-09-02 Remix Therapeutics Inc. Pyridazine dervatives for modulating nucleic acid splicing
WO2021174165A1 (en) 2020-02-28 2021-09-02 Remix Therapeutics Inc. Heterocyclic amides and their use for modulating splicing
WO2021207530A1 (en) 2020-04-08 2021-10-14 Remix Therapeutics Inc. Compounds and methods for modulating splicing
WO2021207550A1 (en) 2020-04-08 2021-10-14 Remix Therapeutics Inc. Compounds and methods for modulating splicing
WO2021207554A1 (en) 2020-04-08 2021-10-14 Remix Therapeutics Inc. Compounds and methods for modulating splicing
WO2021207532A1 (en) 2020-04-08 2021-10-14 Remix Therapeutics Inc. Compounds and methods for modulating splicing
US11806346B2 (en) 2020-05-13 2023-11-07 Chdi Foundation, Inc. HTT modulators for treating Huntington's disease
CN115916757A (zh) * 2020-06-25 2023-04-04 诺华股份有限公司 1，4-二取代的哒嗪化合物的制造方法
WO2021260609A1 (en) * 2020-06-25 2021-12-30 Novartis Ag Process for the manufacture of 1,4-disubstituted pyridazine compounds
WO2022006550A1 (en) 2020-07-02 2022-01-06 Remix Therapeutics Inc. 2-(indazol-5-yl)-6-(piperidin-4-yl)-1,7-naphthyridine derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases
WO2022006543A1 (en) 2020-07-02 2022-01-06 Remix Therapeutics Inc. 5-[5-(piperidin-4-yl)thieno[3,2-c]pyrazol-2-yl]indazole derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases
WO2022060943A1 (en) * 2020-09-16 2022-03-24 Skyhawk Therapeutics, Inc. Compositions for modulating splicing
WO2022103980A1 (en) 2020-11-12 2022-05-19 Ptc Therapeutics Inc. Novel rna transcript
US12115154B2 (en) 2020-12-16 2024-10-15 Srx Cardio, Llc Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9)
US12441728B2 (en) 2021-04-07 2025-10-14 Ventus Therapeutics U.S., Inc. Pyridazine compounds for inhibiting NLRP3
US12312350B2 (en) 2021-04-07 2025-05-27 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
US12281112B2 (en) 2021-04-07 2025-04-22 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
WO2023034833A1 (en) 2021-08-30 2023-03-09 Remix Therapeutics Inc. Compounds and methods for modulating splicing
WO2023034827A1 (en) 2021-08-30 2023-03-09 Remix Therapeutics Inc. Compounds and methods for modulating splicing
WO2023034836A1 (en) 2021-08-30 2023-03-09 Remix Therapeutics Inc. Compounds and methods for modulating splicing
WO2023034812A1 (en) 2021-08-30 2023-03-09 Remix Therapeutics Inc. Compounds and methods for modulating splicing
WO2023034811A1 (en) 2021-08-30 2023-03-09 Remix Therapeutics Inc. Compounds and methods for modulating splicing
WO2023064879A1 (en) 2021-10-13 2023-04-20 Remix Therapeutics Inc. Compounds and methods for modulating nucleic acid splicing
WO2023064880A1 (en) 2021-10-13 2023-04-20 Remix Therapeutics Inc. Compounds and methods for modulating nucleic acid splicing
US12281116B2 (en) 2021-11-17 2025-04-22 Chdi Foundation, Inc. HTT modulators for treating Huntington's disease
WO2023092149A1 (en) * 2021-11-22 2023-05-25 Rgenta Therapeutics, Inc. Heterocyclic substituted 1,3,4-thiadiazole and pyridazine compounds and methods of using the same
WO2023133217A1 (en) 2022-01-05 2023-07-13 Remix Therapeutics Inc. 2-(indazol-5-yl)-6-(piperidin-4-yl)-1,7-naphthyridine derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases
WO2023133225A1 (en) 2022-01-05 2023-07-13 Remix Therapeutics Inc. Compounds and methods for modulating splicing
WO2023133229A2 (en) 2022-01-05 2023-07-13 Remix Therapeutics Inc. Compounds and methods for modulating splicing
US12195460B2 (en) 2022-03-25 2025-01-14 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
US12168657B2 (en) 2022-03-25 2024-12-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US12378222B2 (en) 2022-08-03 2025-08-05 Novartis Ag NLRP3 inflammasome inhibitors
US12312351B2 (en) 2022-10-31 2025-05-27 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
US12398136B2 (en) 2022-10-31 2025-08-26 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
WO2025133325A1 (en) 2023-12-21 2025-06-26 Dbv Technologies Immunotherapeutic methods, compounds, and compositions for treating or preventing celiac disease

Also Published As

Publication number Publication date
WO2017100726A8 (en) 2018-07-05
EP3386511B1 (en) 2021-05-12
US20230201200A1 (en) 2023-06-29
MX2018007022A (es) 2018-11-12
IL281633B (en) 2022-07-01
AU2016366694A1 (en) 2018-06-28
EP3386511A1 (en) 2018-10-17
PH12018501226A1 (en) 2019-02-04
PL3386511T3 (pl) 2021-11-08
CA3007412C (en) 2021-08-24
US11638706B2 (en) 2023-05-02
US10881658B2 (en) 2021-01-05
NZ743147A (en) 2021-03-26
AU2016366694C1 (en) 2021-03-25
CN113717154A (zh) 2021-11-30
MX2021001091A (es) 2022-04-26
EP3386511A4 (en) 2019-01-02
AU2016366694B2 (en) 2020-02-06
KR20180103045A (ko) 2018-09-18
CA3007412A1 (en) 2017-06-15
CA3119019A1 (en) 2017-06-15
CA3119019C (en) 2024-06-11
CN108697709A (zh) 2018-10-23
EA201800367A1 (ru) 2019-02-28
IL259843A (en) 2018-07-31
JP7394893B2 (ja) 2023-12-08
US20190000844A1 (en) 2019-01-03
EP3386511B2 (en) 2024-03-20
IL294124B2 (en) 2024-02-01
HUE055031T2 (hu) 2021-10-28
CN113750101A (zh) 2021-12-07
ES2879995T3 (es) 2021-11-23
KR102488323B1 (ko) 2023-01-12
IL294124B1 (en) 2023-10-01
IL281633A (en) 2021-05-31
JP2021042211A (ja) 2021-03-18
AU2020201380A1 (en) 2020-03-12
AU2020201380B2 (en) 2020-10-08
JP7025508B2 (ja) 2022-02-24
IL294124A (en) 2022-08-01
JP2022060267A (ja) 2022-04-14
IL259843B (en) 2021-04-29
JP2021028331A (ja) 2021-02-25
US20210275526A1 (en) 2021-09-09
MX382671B (es) 2025-03-13
US20200113904A1 (en) 2020-04-16
JP7053760B2 (ja) 2022-04-12
DK3386511T3 (da) 2021-07-05
CN113717154B (zh) 2024-11-15
EP3848035B1 (en) 2025-02-19
US10874672B2 (en) 2020-12-29
SI3386511T1 (sl) 2021-09-30
SG11201804915RA (en) 2018-07-30
KR20220100719A (ko) 2022-07-15
JP2019500352A (ja) 2019-01-10
LT3386511T (lt) 2021-08-25
CN110946865B (zh) 2024-01-26
PT3386511T (pt) 2021-07-14
MX391850B (es) 2025-03-19
CN110946865A (zh) 2020-04-03
EP3848035A1 (en) 2021-07-14

Similar Documents

Publication Publication Date Title
US11638706B2 (en) Methods for treating Huntington's disease
US11858941B2 (en) Heterocyclic and heteroaryl compounds for treating Huntington's disease
WO2019191229A1 (en) Compounds for treating huntington's disease
HK40047883A (en) 1,4-disubstituted pyridazine compounds for treating huntington's disease
HK40116823A (en) Heterocyclic and heteroaryl compounds for treating huntington's disease
US20240132509A1 (en) Heterocyclic and heteroaryl compounds for treating huntington's disease
HK40026829A (en) Methods for treating huntington's disease
HK40043148A (en) Heterocyclic and heteroaryl compounds for treating huntington's disease
HK40043148B (en) Heterocyclic and heteroaryl compounds for treating huntington's disease
EA040315B1 (ru) Способы лечения болезни хантингтона

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16874024

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3007412

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 259843

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 12018501226

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 11201804915R

Country of ref document: SG

Ref document number: 2018529967

Country of ref document: JP

Ref document number: MX/A/2018/007022

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 20187016467

Country of ref document: KR

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2016366694

Country of ref document: AU

Date of ref document: 20161211

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 201800367

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 2016874024

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2016874024

Country of ref document: EP

Effective date: 20180710